Shire PLC Company Profile (LON:SHP)

About Shire PLC (LON:SHP)

Shire PLC logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals - NEC
  • Sub-Industry: N/A
  • Symbol: LON:SHP
  • CUSIP: N/A
  • Web:
  • Market Cap: £34.93 billion
  • Outstanding Shares: 906,400,000
Average Prices:
  • 50 Day Moving Avg: GBX 4,176.59
  • 200 Day Moving Avg: GBX 4,516.78
  • 52 Week Range: GBX 3,787 - GBX 5,377
  • Trailing P/E Ratio: 52.03
  • P/E Growth: 0.96
Sales & Book Value:
  • Annual Revenue: £14.58 billion
  • Price / Sales: 2.40
  • Book Value: GBX 34.49 per share
  • Price / Book: 1.12
  • Dividend Yield: 0.5%
  • EBIDTA: £5.76 billion
  • Net Margins: 6.33%
  • Return on Equity: 3.18%
  • Return on Assets: 1.43%
  • Average Volume: 2.60 million shs.
Frequently Asked Questions for Shire PLC (LON:SHP)

What is Shire PLC's stock symbol?

Shire PLC trades on the London Stock Exchange (LON) under the ticker symbol "SHP."

How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?

Shire PLC announced a dividend on Thursday, August 3rd. Investors of record on Thursday, September 7th will be given a dividend of GBX 3.85 per share on Friday, October 20th. This represents a yield of 0.1%. The ex-dividend date of this dividend is Thursday, September 7th. The official announcement can be seen at this link. View Shire PLC's Dividend History.

When will Shire PLC make its next earnings announcement?

Shire PLC is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for Shire PLC.

Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?

17 brokers have issued 12-month price objectives for Shire PLC's stock. Their forecasts range from GBX 4,400 to GBX 7,500. On average, they anticipate Shire PLC's stock price to reach GBX 5,964.63 in the next twelve months. View Analyst Ratings for Shire PLC.

Who are some of Shire PLC's key competitors?

Who are Shire PLC's key executives?

Shire PLC's management team includes the folowing people:

  • Flemming Ornskov M.D., Chief Executive Officer, Executive Director
  • Jeffrey Poulton, Chief Financial Officer, Executive Director
  • William Mordan, General Counsel, Company Secretary
  • Perry Sternberg, Head - U.S. Commercial
  • Kim Stratton, Head - International Commercial
  • Philip J. Vickers, Head - Research and Development
  • Matthew Walker, Head - Technical Operations
  • Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
  • Olivier Bohuon, Non-Executive Director
  • Ian T. Clark, Non-Executive Director

How do I buy Shire PLC stock?

Shares of Shire PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Shire PLC's stock price today?

One share of Shire PLC stock can currently be purchased for approximately GBX 3,854.

MarketBeat Community Rating for Shire PLC (LON SHP)
Community Ranking:  4.2 out of 5 (   )
Outperform Votes:  1,052 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  1,255
MarketBeat's community ratings are surveys of what our community members think about Shire PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Shire PLC (LON:SHP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 13 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: GBX 5,964.63

Analysts' Ratings History for Shire PLC (LON:SHP)
DateFirmActionRatingPrice TargetDetails
8/15/2017Shore CapitalReiterated RatingBuyView Rating Details
8/11/2017Liberum CapitalLower Price TargetHoldGBX 4,900 -> GBX 4,400View Rating Details
8/11/2017Barclays PLCDowngradeEqual weightView Rating Details
8/9/2017Berenberg BankReiterated RatingBuyGBX 6,000View Rating Details
8/7/2017Jefferies Group LLCLower Price TargetBuyGBX 5,600 -> GBX 5,250View Rating Details
8/4/2017Beaufort SecuritiesReiterated RatingLong Term BuyGBX 6,200 -> GBX 4,900View Rating Details
8/4/2017Deutsche Bank AGReiterated RatingBuyGBX 6,000View Rating Details
8/4/2017J P Morgan Chase & CoReiterated RatingOverweightView Rating Details
8/4/2017Credit Suisse GroupReiterated RatingOutperformGBX 5,350View Rating Details
7/12/2017Societe GeneraleReiterated RatingBuyGBX 7,500View Rating Details
7/7/2017Royal Bank Of CanadaReiterated RatingOutperformView Rating Details
7/6/2017HSBC Holdings plcUpgradeHoldGBX 4,450View Rating Details
6/28/2017Goldman Sachs Group, Inc. (The)Lower Price TargetConviction-BuyGBX 6,800 -> GBX 6,400View Rating Details
6/22/2017Citigroup Inc.Reiterated RatingBuyGBX 6,500View Rating Details
4/3/2017BNP ParibasReiterated RatingOutperformGBX 5,900View Rating Details
1/9/2017Bryan, Garnier & CoReiterated RatingBuyGBX 6,800View Rating Details
11/7/2016AlphaValueReiterated RatingBuyGBX 6,714View Rating Details
11/3/2016Bank of America CorporationReiterated RatingBuyGBX 6,970View Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightGBX 5,600View Rating Details
3/15/2016Sanford C. BernsteinReiterated RatingOutperformGBX 5,000View Rating Details
1/12/2016S&P Equity ResearchReiterated RatingBuyView Rating Details
12/3/2015InvestecDowngradeSellView Rating Details
11/3/2015Kepler Capital MarketsLower Price TargetBuyGBX 6,000 -> GBX 5,900View Rating Details
(Data available from 8/16/2015 forward)


Earnings History for Shire PLC (LON:SHP)
Earnings by Quarter for Shire PLC (LON:SHP)
Earnings History by Quarter for Shire PLC (LON SHP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2017S1 2017$0.84N/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Shire PLC (LON:SHP)
Current Year EPS Consensus Estimate: $5.00 EPS


Dividend History by Quarter for Shire PLC (LON SHP)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/3/2017GBX 3.850.1%9/7/20179/7/201710/20/2017
2/16/2017GBX 20.640.43%3/9/20173/9/20174/25/2017
8/2/2016GBX 3.510.07%9/8/20169/8/201610/7/2016
2/11/2016GBX 15.320.44%3/10/20163/10/20164/12/2016
7/23/2015GBX 2.690.05%9/3/20159/3/201510/2/2015
7/18/2014GBX 2.240.04%9/3/20149/3/201410/3/2014
2/13/2014GBX 10.210.31%3/5/20143/5/20144/8/2014
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Shire PLC (LON:SHP)
Insider Trades by Quarter for Shire PLC (LON:SHP)
Insider Trades by Quarter for Shire PLC (LON:SHP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/30/2017Dominic BlakemoreInsiderBuy152GBX 4,255£6,467.60
3/31/2017William BurnsInsiderBuy136GBX 4,742£6,449.12
12/16/2016Olivier BohuonInsiderBuy141GBX 4,528£6,384.48
9/30/2016Dominic BlakemoreInsiderBuy133GBX 5,010£6,663.30
6/30/2016Bohuon,OlivierInsiderBuy134GBX 4,463£5,980.42
3/31/2016Bohuon,OlivierInsiderBuy133GBX 3,908£5,197.64
2/15/2016Bohuon,OlivierInsiderBuy1,000GBX 3,552£35,520
2/12/2016Burns,WilliamInsiderBuy1,250GBX 3,563£44,537.50
12/18/2015Burns,WilliamInsiderBuy156GBX 4,457£6,952.92
9/30/2015Blakemore ,DominicInsiderBuy129GBX 4,498£5,802.42
6/30/2015Kappler,David JInsiderBuy126GBX 51.05GBX 6,432.30
3/31/2015Susan KilsbyInsiderBuy375GBX 5,327£19,976.25
12/19/2014Steven GillisInsiderBuy228GBX 4,654£10,611.12
10/30/2014Steven GillisInsiderBuy381GBX 4,098£15,613.38
(Data available from 1/1/2013 forward)


Headline Trends for Shire PLC (LON:SHP)
Latest Headlines for Shire PLC (LON:SHP)
DateHeadline logoShire Announces Submission Of MAA For Lifitegrast - Quick Facts - August 16 at 7:29 AM logoShire PLC (LON:SHP) Price Target Lowered to GBX 5,250 at Jefferies Group LLC - August 7 at 6:34 AM logoEdited Transcript of SHP.L earnings conference call or presentation 3-Aug-17 1:00pm GMT - August 5 at 7:00 AM logoBHP Billiton plc and Shire plc could be the FTSE 100’s best bargains - July 30 at 6:10 AM logoShire PLC (SHP) Stock Rating Reaffirmed by J P Morgan Chase & Co - July 23 at 10:04 AM logo[$$] Shire boss says share price at odds with drugs pipeline - July 16 at 3:55 PM logoShire PLC (LON:SHP) Stock Rating Upgraded by HSBC Holdings plc - July 9 at 2:16 PM logoRoyal Bank Of Canada Reiterates Outperform Rating for Shire PLC (SHP) - July 8 at 8:32 AM logoShire Completes NDA Filing for Hemophilia Drug with FDA - July 7 at 11:14 AM logoBritish ministers call for post-Brexit drug deal with EU - July 4 at 7:20 AM logoShire PLC (LON:SHP) Price Target Cut to GBX 6,400 by Analysts at Goldman Sachs Group, Inc. (The) - July 3 at 10:46 PM logoShire PLC's (LON:SHP) "Buy" Rating Reiterated at Deutsche Bank AG - July 3 at 5:10 PM logoBarclays PLC Reiterates Overweight Rating for Shire PLC (LON:SHP) - July 3 at 1:33 PM logoInsider Buying: Shire PLC (LON:SHP) Insider Acquires 152 Shares of Stock - July 3 at 1:20 PM logoShire PLC's (SHP) Hold Rating Reiterated at Liberum Capital - July 2 at 10:34 PM logoShire PLC (SHP) Given Consensus Rating of "Buy" by Brokerages - June 30 at 11:18 AM logoShire PLC (SHP) Given Buy Rating at Citigroup Inc. - June 25 at 10:02 AM logoShire Says EMA Validates Veyvondi MAA For Treatment Of Von Willebrand Disease - June 22 at 1:31 PM logoShire (SHPG) Receives MAA Validation for Veyvondi by EMA - June 22 at 1:31 PM logoShire : FDA Approves Mydayis, New Once-Daily Option For ADHD Symptom Control - June 21 at 5:20 AM logoShire plc: U.S. FDA Approves Mydayis (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older - June 21 at 5:20 AM logoShire PLC's (SHP) Overweight Rating Reaffirmed at J P Morgan Chase & Co - June 19 at 10:08 PM logoShire PLC (SHP) Given New GBX 6,000 Price Target at Deutsche Bank AG - June 18 at 10:20 PM logoShire PLC (SHP) Given Hold Rating at Liberum Capital - June 18 at 10:46 AM logoShire PLC (SHP) Given "Overweight" Rating at Barclays PLC - June 11 at 9:38 AM logoJefferies Group LLC Trims Shire PLC (SHP) Target Price to GBX 5,600 - June 11 at 12:26 AM logoShire PLC (SHP) PT Lowered to GBX 6,000 at Berenberg Bank - June 8 at 6:36 PM logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shire plc - SHPG - June 7 at 7:40 PM logoBrexit Winners: Why JPMorgan Is Buying UK Stocks - June 3 at 12:20 AM logoShire PLC (SHP) Lowered to "Hold" at Liberum Capital - June 1 at 1:40 PM logoShire PLC (SHP) Given "Overweight" Rating at JPMorgan Chase & Co. - May 28 at 3:56 PM logoDeutsche Bank AG Reiterates Buy Rating for Shire PLC (SHP) - May 28 at 3:56 PM logoShire PLC's (SHP) Overweight Rating Reiterated at Barclays PLC - May 28 at 2:38 PM logoShire PLC (SHP) Lowered to Reduce at HSBC Holdings plc - May 28 at 2:02 PM logoLiberum Capital Reiterates Buy Rating for Shire PLC (SHP) - May 26 at 6:38 PM logoShire PLC's (SHP) "Buy" Rating Reiterated at Citigroup Inc - May 18 at 10:20 PM logoShire's swelling disorder drug moves closer to U.S. approval - Nasdaq - May 18 at 1:08 PM logoShire's Investigational Treatment Lanadelumab Reduces Hereditary Angioedema Monthly Attack Rate by 87% Versus Placebo in Phase 3 26-week Pivotal Trial - May 18 at 1:08 PM logoShire ADRs jump almost 7% premarket after positive trial of Angioedema treatment - May 18 at 1:08 PM logoThe Lancet Publishes Phase 2 Results from Shire's Investigational Anti-MAdCAM Antibody Showing Significantly Increased Remission Rates in Patients with Moderate-to-Severe Ulcerative Colitis - May 18 at 1:08 PM logo​Shire gains $2B in market cap as rare disease drug aces late-stage trial - May 18 at 1:08 PM logoShire's swelling disorder drug moves closer to U.S. approval - May 18 at 1:08 PM logoShire Continues 20-Year Commitment to ADHD with New Research at 2017 Annual Meeting of American Psychiatric Association - May 16 at 9:16 AM logoShire Plc – Value Analysis (LONDON:SHP) : May 15, 2017 - May 15 at 7:02 PM logoDeutsche Bank AG Cuts Shire PLC (SHP) Price Target to GBX 6,100 - May 14 at 11:30 PM logoShire PLC's (SHP) "Buy" Rating Reaffirmed at Berenberg Bank - May 14 at 2:08 PM logoShire Plc breached its 50 day moving average in a Bullish Manner : SHP-GB : May 12, 2017 - May 13 at 12:28 AM logoShire PLC (SHP) Receives Average Rating of "Buy" from Analysts - May 9 at 9:24 AM logoShire PLC (SHP) Rating Reiterated by Citigroup Inc - May 7 at 7:34 PM logoEdited Transcript of SHP.L earnings conference call or presentation 2-May-17 1:00pm GMT - May 3 at 10:54 AM


Social activity is not available for this stock.


Shire PLC (SHP) Chart for Wednesday, August, 16, 2017

This page was last updated on 8/16/2017 by Staff